Financial Planning for Joint Replacement Surgeons

Joint replacement is the highest-volume orthopedic subspecialty by case count — and since 2020, one of the most financially consequential decisions has shifted from hospitals to surgeons: whether to own the facility where you operate. Generic physician advice doesn't address TJA ASC economics, robotics capital calls, or how the 2026 CMS revision expansion changes your partnership calculus.

Why joint replacement financial planning is different

The MGMA 2025 survey (2024 actuals) puts the median for orthopedic surgery hip/joint reconstruction specialists at $669,591 — competitive but meaningfully below spine's $875K median, reflecting a higher proportion of hospital-employed surgeons and procedure mix.¹ Add surgeon-owned ASC distributions and the picture changes significantly: a TJA surgeon partner in a productive ASC clears $900K–$1.3M in total annual income.

Three structural factors make the financial picture for joint replacement surgeons distinct from both other ortho subspecialties and generic physician planning:

1. The ASC opportunity arrived late — and is still expanding. CMS added total knee arthroplasty (TKA) and total hip arthroplasty (THA) to the ASC covered procedures list in 2020 — meaning facility fees that went exclusively to hospitals before 2020 can now flow to surgeon-owned ASCs. In January 2026, CMS further expanded the list to include complex total joint revisions at ASCs.² If you're building or buying into an ASC now, you're entering at the right point of the expansion curve.
2. Robotics is a partnership-level capital decision, not a hospital cost. Stryker Mako, Zimmer Biomet Rosa Knee, Smith+Nephew CORI, and DePuy Velys systems cost $1M–$2M or more. In hospital employment, the hospital buys it. In private practice, the partners fund it — often via capital call. The financing structure, fee-per-case lease options, and vendor relationship terms are negotiating points most surgeons never see until they're signing.
3. Physical demand compresses the earning window. High-volume TJA surgery — 500–700+ procedures per year at peak — is physically demanding in a way that limits most surgeons' peak volume years to ages 40–56. That's a narrower compounding window than academic specialties or procedure-light practices. Front-loaded retirement savings matter more for joint replacement surgeons than for many peers.

Income dynamics across the joint replacement career arc

Joint replacement income follows a pattern familiar to most orthopedic subspecialties, but with timing shifts driven by the hospital-vs-private split.

Fellowship → Associate (years 1–4): New joint replacement attendings typically earn $520K–$640K in year one. The hospital-employed path is common for TJA surgeons early in their career — hospitals want predictable elective procedure volume, and the capital requirements (OR scheduling, implant inventory, robotics) make the employed path financially easier to enter. This period is the compounding window: student loans from medical training need a decision point, first-year disability insurance enrollment has permanent coverage advantages, and the retirement savings gap between hospital-employed and private practice surgeons starts accumulating from day one.

Partnership track (years 4–8): Surgeons choosing private practice buy into both the group practice and, ideally, an ASC equity stake. The buy-in cost — $200K–$400K for an existing ASC unit, or a larger commitment for a de novo build — is the highest-value financial decision in most TJA careers. Unlike the spine subspecialty, where ASC economics have been established for years, the joint replacement ASC market is still maturing: negotiating terms, evaluating case volume projections for a relatively new category, and understanding how the 2026 revision expansion changes distributable income are questions that require TJA-specific expertise.

Peak earning years (late 30s–mid 50s): A full-partner joint replacement surgeon with ASC equity running 500+ primary cases per year earns $700K–$950K in clinical income plus $200K–$500K in annual ASC distributions. Total compensation of $900K–$1.3M is achievable for high-volume partners in productive facilities. Unlike spine, where neurological case complexity keeps volumes modestly lower, joint replacement volume-driven economics reward surgeons who can maintain throughput — and ASC ownership amplifies every case through facility fees.

Late career (mid 50s–60s): Physical longevity at high TJA volume is not a given. The combination of standing, repetitive motion, and ergonomic demands of hip and knee arthroplasty leads many surgeons to begin tapering volume by the late 50s — not always by choice. Retirement savings must be structured assuming an income cliff at 56–62, not a gradual taper to 65+. ASC equity, if held, continues generating distributions even as surgical volume declines — which is the best late-career financial hedge a joint replacement surgeon has.

Practice setting decisions for joint replacement surgeons

The hospital-vs-private employment split is more balanced in total joint arthroplasty than in most other orthopedic subspecialties — hospitals rely on TJA volume for DRG reimbursement and have strong financial incentives to employ high-volume surgeons. That gives employed surgeons more compensation leverage, but doesn't close the long-run wealth gap.

Hospital employment

A hospital-employed joint replacement surgeon in a non-academic system typically earns $650K–$800K/year — base, RVU production bonus, and shift/call differential. Malpractice, tail coverage, and implant costs fall to the employer. What you give up: ASC ownership (most hospital employment agreements prohibit it outright), the ability to control implant selection and vendor relationships, and the 401(k) ceiling. Hospital employees are capped at the $24,500 employee deferral; private practice partners can stack a 401(k) with a cash balance plan for $200K–$400K+ annually in pre-tax savings.

Private practice without ASC equity

Private practice joint replacement surgeons who operate at hospital ORs or hospital-affiliated outpatient centers capture professional fees but not facility fees. Income is typically $750K–$950K. This is often a transitional arrangement: the group's goal is building or acquiring ASC ownership. A surgeon 3–5 years into a private group with no ASC path should ask directly what the timeline is — and whether one exists.

Private practice with ASC equity (optimal for most)

A partner in a private TJA practice with an affiliated surgeon-owned ASC captures both fee streams. Professional income of $700K–$900K plus annual distributions of $200K–$500K produces total compensation of $900K–$1.3M for a high-volume surgeon. The 2020 CMS expansion made primary cases feasible; the 2026 revision expansion adds higher-reimbursed complex cases. Use the ASC investment ROI calculator to model the full economics of a specific buy-in offer.

Academic / teaching hospital

Academic joint replacement surgeons typically earn $500K–$650K. Complex revision referrals, research, and training are the tradeoff for lower total compensation. ASC ownership is generally prohibited by institutional conflict-of-interest policies. The right choice for surgeons who genuinely value the academic mission; a poor choice for surgeons primarily focused on wealth accumulation.

ASC ownership for joint replacement: the 2020–2026 expansion window

The CMS inpatient-only list removal for total knee arthroplasty (effective CY2020) and total hip arthroplasty (also CY2020) was the defining regulatory shift in joint replacement economics in a generation.² Before 2020, hospitals captured 100% of facility fees on Medicare TJA cases. After 2020, surgeon-owned ASCs could perform primary TKA and THA on Medicare patients and bill the ASC facility fee directly.

The 2026 expansion extended ASC eligibility to complex total joint revisions — cases with significantly higher reimbursement that had previously been limited to inpatient settings.³ For surgeons building or evaluating TJA ASC investments now, the case mix economics are materially better than at the initial 2020 expansion.

The ASC economics for a high-volume TJA facility:

• Buy-in cost: $200K–$400K for a unit in an established TJA ASC; $300K–$600K+ for founding equity in a de novo build with robotics.
• Annual distributions per surgeon partner: $200K–$500K at a high-volume facility with favorable payer mix.
• Break-even timeline: typically 2–4 years from buy-in at mature distribution rates.
• Exit: TJA ASCs have attracted corporate buyers (USPI, SurgCenter Development) at 8–12× EBITDA, with the revision expansion likely supporting higher multiples as case mix improves.

Key diligence before any TJA ASC investment: What is the current payer mix? How many primary vs revision cases annually, and how does the ratio shift with the 2026 expansion? Is the ASC already set up for robotics, or is there a capital call pending? See the full analysis in the ASC ownership guide.

Robotics: the partnership capital call most surgeons don't model

Robotic-assisted total joint arthroplasty has shifted from differentiator to expected standard at high-volume practices. Stryker Mako, Zimmer Biomet Rosa Knee, Smith+Nephew CORI, and DePuy Velys systems cost $1M–$2M per system — a cost that falls on the hospital in employed settings and on the partnership in private practice.

For surgeons evaluating a private group or ASC investment, three robotics-related questions deserve explicit answers before signing:

1. Who funded the existing system? If partners contributed capital to buy the system, and you're buying in now at a unit price calculated before that cost was absorbed, you may be getting credit for a fully-depreciated asset — or you may be overpaying for a system that needed replacement capital.
2. What is the fee-per-case arrangement vs outright ownership? Some groups operate on a per-case lease or cost-per-use model rather than buying the system. This eliminates capital call risk but reduces operating leverage — you pay per procedure rather than spreading a fixed cost over volume.
3. Which system, and what are the implant vendor tie-ins? Robotics systems are often paired with specific implant families (Mako with Stryker implants, Rosa with Zimmer, etc.). As a partner, your implant choice may be constrained by the system purchased — affecting per-case economics and your clinical preferences. This is a negotiating point on buy-in terms, not just a clinical consideration.

Malpractice for joint replacement surgeons

Joint replacement has a materially lower malpractice risk profile than spine — no neurological structures at primary risk, established procedure protocols, and lower per-claim exposure. Annual premiums for joint replacement surgeons run $40–70K/year in most states for claims-made coverage, versus $80–120K for spine.⁴

Common TJA claim categories: periprosthetic joint infection, DVT/pulmonary embolism, implant failure or loosening, leg length discrepancy (THA), and instability. These claims tend to be moderate in size but require 3–7 year tail coverage from the date of surgery — critical to price correctly at every practice transition.

One emerging malpractice dynamic to watch: as robotic-assisted TJA becomes the dominant technique at high-volume centers, the standard of care argument can shift. A surgeon performing manual TJA at a facility that has robotics available may face a stronger plaintiff argument that care deviated from standard. This is an early-stage liability evolution, but it is something malpractice carriers are beginning to discuss in premium modeling. For the full tail cost and occurrence-vs-claims-made analysis, see the malpractice tail coverage guide.

Tax stacking for joint replacement surgeons at $700K–$1.3M

A private practice joint replacement surgeon earning $700K–$1.3M in combined income faces a 37% federal marginal rate on most of it. The difference between a surgeon who maximizes every pre-tax vehicle and one who limits contributions to a basic employer 401(k) can exceed $80,000–$180,000 in annual tax savings depending on age and plan design.

The four-vehicle stack for private practice joint replacement surgeons

1. Solo 401(k) or group 401(k): $72,000/year total (employee + employer contributions), or $83,250 ages 60–63 with the SECURE 2.0 super catch-up. At a 37% marginal rate, $72,000 in pre-tax contributions saves $26,640 in federal tax annually. Source: IRS Notice 2025-67 (2026 limits).⁵
2. Cash balance plan: A defined benefit plan stacked on top of the 401(k). Annual contributions of $100K–$280K for surgeons aged 45–60, actuarially determined. Fully deductible to the practice entity. A 49-year-old joint replacement surgeon contributing $180,000/year to a cash balance plan saves $66,600/year in federal taxes — $666,000 over ten years before investment returns. See the full analysis in the cash balance plan guide.
3. Backdoor Roth IRA: $7,000/year (under 50), $8,000 (50+). After-tax contribution, immediate conversion before earnings accumulate. Tax-free growth with no RMDs. Modest dollar amount but compounds asymmetrically over a 25–30 year window.
4. HSA: $8,750/year family (2026). Triple-tax-advantaged. Invest rather than spend — after 15 years at 7% real return, $8,750/year produces approximately $220,000 in tax-free retirement assets.

Hospital-employed joint replacement surgeons are typically limited to the $24,500 employee 401(k) deferral. The gap between a hospital employee and a private practice surgeon using all four vehicles can exceed $250,000 per year in pre-tax retirement contributions — compounding at 7% over 20 years creates a seven-figure wealth differential from tax-advantaged savings alone. Use the retirement tax stacking calculator to model your annual ceiling by age and practice type.

Career longevity and front-loaded savings

High-volume TJA surgery — 500–700 primary cases per year at peak — is physically demanding. Repetitive motion, long OR cases, and postural demands mean that most joint replacement surgeons cannot maintain peak volume indefinitely. The median age at which total joint surgeons begin meaningfully reducing case volume is 54–58, with many tapering before 60.¹

The implications for financial planning are structural, not speculative: if peak earning years are 42–57 rather than 42–65, savings rate and tax shelter use must be proportionally higher in the earlier years. A joint replacement surgeon who delays maximizing retirement contributions until age 50 has already lost 8–12 years of peak-earning compounding that cannot be recovered in the compressed window remaining.

The best late-career hedge for a TJA surgeon is retained ASC equity: distributions that continue even as surgical volume declines. Surgeons who sell or relinquish their ASC equity before reducing volume are giving up the most valuable passive income stream in the portfolio. For surgeons considering practice sale or group transition, the timing of ASC equity disposition relative to practice volume is a key variable — not an afterthought.